Indian Journal of Clinical Biochemistry

, Volume 21, Issue 1, pp 173–176 | Cite as

Significance of tumor markers in lung cancer

  • P. P. Mumbarkar
  • A. S. Raste
  • M. S. Ghadge


The objective was to test the utility of the cytokeratins CYFRA 21-1, tissue polypeptide specific antigen (TPS), Neuron specific enolase (NSE) and Carcino Embryonic antigen (CEA) in patients with lung cancer and in the pleural fluid of the patients with lung cancer and also the predicting ability of these tumor markers with respect to the histological types [including non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] and pathological stages. 40 normal subjects and 222 cases of histological proven lung cancer were studied. The findings suggest that TPS and CYFRA 21-1, are useful serum markers for the diagnosis of NSCLC and NSE seems to be useful tumor marker for monitoring course of patients especially SCLC. The combined use of these cytokeratin markers TPS and CYFRA 21-1 may provide additional information for prognosis.


Lung Cancer Pleural Effusion Tumor Marker Small Cell Lung Cancer Lung Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pamies, R.J. and Crawford, D.R. (1996). Tumor markers: an update Med. Clin. North Am. 80, 185–199.PubMedCrossRefGoogle Scholar
  2. 2.
    Coombes, R.C. and Powels, T.J. (1982). Tumor markers in the management of human cancer. In: Deeley, T.J. ed. Topical reviews in radiotherapy and oncology. Bristol, UK: Wright PGS, 1982: 39.Google Scholar
  3. 3.
    Buccheri, G. and Ferrigno, D. (2001). Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 34 (suppl), S65-S69.PubMedCrossRefGoogle Scholar
  4. 4.
    Bjorklund, B. (1978). Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. In: Schonfeld H. ed. Laboratory testing for cancer. Basel. Switzerland: Karger, 16–31.Google Scholar
  5. 5.
    Broers, J.L., Ramaekers, F.C., Rot, al. (1988). Cytokeratins in different types of lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res., 48, 3221–3229.PubMedGoogle Scholar
  6. 6.
    Buccheri, G. (1999). Tumor markers: clinical meaning and use. In: Brambilla, C., Brambilla, E. eds. Lung tumors. New York, NY: Marcel Dekker, 435–452.Google Scholar
  7. 7.
    van Putten, J.W., Baas, P., Codrington, al. (2001). Activity of single agent gemcitabine as second line treatment after previous chemotherapy or radiotherapy in advanced non small-cell lung cancer. Lung Cancer 33, 289–298.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrigno, D. and Buccheri, G. (1995). Clinical applications of serum markers for lung cancer. Bespir. Med. 89, 587–597.CrossRefGoogle Scholar
  9. 9.
    Lai, R.S., Chen, C.C., Lee, P.C. and Lu, J.Y. (1999). Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn. J. Clin. Oncol. 29 (9), 421–424.PubMedCrossRefGoogle Scholar
  10. 10.
    Buccheri, G., Ferrigno, D., Sartoris, al. (1987). Tumor markers in bronchogenic carcinoma: superiority of tissue polypeptide antigen to carcino embryonic antigen and carbohydrate antigenic determinant 19-9. Cancer, 60, 42–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Barlesi, F., Gimenez, C., Torre, J.P., Doddoli, C., Mancini, J., Greillier, al. (2004). Prognostic value of combination of CYFRA 21-1, CEA and NSE in patients with advanced non small cell lung cancer. Respn. Med. 98 (4), 357–362.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2006

Authors and Affiliations

  • P. P. Mumbarkar
    • 1
  • A. S. Raste
    • 1
  • M. S. Ghadge
    • 1
  1. 1.Department of BiochemistryTata Memorial HospitalMumbai

Personalised recommendations